Dolby Laboratories, INC Form 4 insider transactions

Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.

NYSE
Dagmar Dolby and 2 others reported changes in beneficial ownership of Dolby Laboratories, Inc. common stock on October 2, 2026.
NYSE
Marc Whitten, President and CEO and a Director of Dolby Laboratories, Inc., reported multiple transactions in common stock on September 15, 2026.
NYSE
John D Couling, SVP, Entertainment of Dolby Laboratories, Inc., received 48,076 shares of common stock on September 15, 2026.
NYSE
Mark Andrew Sherman, EVP, Gen. Counsel & Secretary of Dolby Laboratories, Inc., received 48,076 shares of common stock on September 15, 2026.
NYSE
John D Couling, SVP, Entertainment of Dolby Laboratories, Inc., sold 7,667 shares of common stock on September 1, 2026 for $61.05 per share.
NYSE
Dagmar Dolby and 1 other reported changes in beneficial ownership of Dolby Laboratories, Inc. common stock on August 28, 2026.
NYSE
Ryan Nicholson, VP, CAO and Corp. Controller of Dolby Laboratories, Inc., sold 1,183 shares of common stock on August 25, 2026 for $65.28 per share.
NYSE
Shriram Revankar, SVP, Advanced Technology Group of Dolby Laboratories, Inc., sold 3,000 shares of common stock on August 14, 2026 for $62.71 per share.
NYSE
Ryan Nicholson, VP, CAO and Corp. Controller of Dolby Laboratories, Inc., sold 357 shares of common stock on August 4, 2026 for $60.63 per share.
NYSE
John D Couling, SVP, Entertainment of Dolby Laboratories, Inc., sold 7,667 shares of common stock on August 3, 2026.
NYSE
Dolby Laboratories SVP John Couling reported transactions involving Class A Common Stock, including the acquisition of shares under an employee stock option and the sale of shares.
NYSE
John D. Couling, SVP of Entertainment at Dolby Laboratories, Inc., reported transactions involving Class A Common Stock, including acquisitions and dispositions, executed under a Rule 10b5-1 trading plan.
NYSE
Dolby Laboratories SVP and Chief Marketing Officer Todd Pendleton sold 11,876 shares of Class A common stock on May 22, 2026.
NYSE
SVP of Advanced Technology Group Shriram Revankar sold 3,000 shares of Dolby Laboratories stock under a 10b5-1 trading plan.
NYSE
Dolby Laboratories SVP and CFO Robert Park sold 4,895 shares of Class A common stock on May 12, 2026.
NYSE
Dolby Laboratories SVP John Couling exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.
NYSE
Dolby Laboratories Director Emily Rollins reported a transaction involving 1,000 shares of Class A Common Stock on April 1, 2026.
NYSE
Dolby Laboratories director and 10% owner Dagmar Dolby reported a charitable gift of 10,000 Class A shares and an estate planning transfer of 1 million Class B shares.
NYSE
Dagmar Dolby, a Director and 10% owner of Dolby Laboratories, converted and gifted 380,000 shares of Class A Common Stock to a charitable organization.
NYSE
Dolby Laboratories CEO Kevin Yeaman transferred 145,252 employee stock options to a revocable trust for estate planning purposes.
NYSE
Dolby Laboratories Director Simon Segars received a grant of 3,908 restricted stock units, increasing his beneficial ownership to 47,150 shares.
NYSE
Dolby Laboratories Director David Dolby was granted 3,908 restricted stock units, increasing his beneficial ownership to 92,718 shares.
NYSE
Dolby Laboratories Director Emily Rollins was granted 3,908 restricted stock units, increasing her beneficial ownership.
NYSE
Dolby Laboratories Director Peter Gotcher received an award of 3,908 restricted stock units, aligning his interests with shareholders.
NYSE
Dolby Laboratories director Anjali Sud received a grant of 3,908 restricted stock units, aligning her interests with shareholders.
NYSE
Dolby Laboratories Director Tony Prophet received a grant of 3,908 restricted stock units, increasing his beneficial ownership to 13,015 shares.
NYSE
Dolby Laboratories Director Avadis Tevanian received an award of 3,908 restricted stock units as part of his compensation.
NYSE
Dolby Laboratories' SVP of Entertainment, John D. Couling, reported a planned future sale of 6,667 Class A Common Stock shares at $64.885 per share under a Rule 10b5-1 plan.
NYSE
Dolby Laboratories' SVP of Entertainment, John D. Couling, reported new grants of restricted stock units, performance-based units, and stock options, alongside shares withheld for tax obligations.
NYSE
Dolby Laboratories VP, CAO, and Corporate Controller Ryan Nicholson reported the grant of 9,032 restricted stock units and subsequent tax-related dispositions of shares.